Peer Exchange

Our Peer Exchange™ program provides a multi-stakeholder perspective on important issues that providers, pharmacists, payers, and patients grapple with as they step into the world of biosimilars.
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH, conclude the Peer ExchangeTM with a discussion of the importance of putting patients at the center of the biosimilar conversation.

 
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH, discuss how biosimilars are making a difference to patients in terms of cost and access.
 
Christy M. Gamble, JD, DrPH, MPH, addresses the need for diversity in clinical trials.
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH talk about diversity, or the lack thereof, in clinical trials and the ramifications that a lack of diversity has for patients.
Amanda Forys, MSPH, and Christy M. Gamble, JD, DrPH, MPH, weigh the question of whether manufacturers' patient assistance programs are doing enough to address high drug costs. 
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH, share their thoughts about patient assistance programs for high-cost drugs.
 
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH, examine whether the changes CMS has made this year will incentivize private payers to encourage biosimilar use, and discuss pharmacy-level substitution of biosimilars for reference biologics.
Amanda Forys, MSPH and Christy M. Gamble JD, DrPH, MPH, discuss CMS’ recent changes to reimbursement for biosimilars, and the impacts that these changes will have on patients under Medicare Part B and Part D.
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH address the pros and cons of multiple scenarios regarding rebates.
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH, discuss what patients are paying for biologics and biosimilars, and how cost affects access.
Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities



Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2018 Intellisphere, LLC. All Rights Reserved.